Sense and nonsense:: an essay on schizophrenia research ethics
Introduction
The Toronto Conference on Research Ethics provides an excellent opportunity to consider certain issues in ethics as applied to research with severely mentally ill persons. It is important that views from many vantages be considered in the discussion of these issues. The content of this essay will be focused on issues in schizophrenia research. This is an area of much heat and misunderstanding in the public discussion. The discussion of a few selected issues is offered in the hope that it will increase rational consideration of optimal research procedures and diminish the influence of recommendations based on a misunderstanding of the actual circumstances of clinical investigation. The discussion will be divided into sections on informed consent, on the idea of withdrawing medication, and on the several perspectives in which research protocols are judged.
Section snippets
Informed consent
The conduct of clinical investigation is a noble enterprise and a foundation of scientific medicine. Much human suffering and enhancement of quality of human life emanate directly from clinical investigations. The clinician investigator has many responsibilities, but foremost among them is the protection of the safety, welfare, and dignity rights of persons who participate as subjects in investigations. Informed consent is at the heart of the processes that protect the autonomy, dignity, and
Perspectives on research ethics
There are several vantages from which the ethics of particular protocols can be addressed. In each of these it is important that considerations meet a commonsense standard. Instances to consider include:
References (13)
- et al.
Clinical issues in the assessment of competency
Am. J. Psychiatry
(1981) - Appelbaum, P.S., Grisso, T., 1996. MacArthur Competence Assessment Tool—Clinical Research Version. University of...
- et al.
Early intervention, time-limited targeted pharmacotherapy in schizophrenia
Schizophr. Bull.
(1983) - et al.
The rationale and ethics of medication-free research in schizophrenia
Arch. Gen. Psychiatry
(1997) - et al.
Neuroleptic withdrawal in schizophrenic patients: a review of the literature
Arch. Gen. Psychiatry
(1995) - Hilts, P.J., 1994a. Agency faults a UCLA study for suffering of mental patients. New York Times, 10...
Cited by (32)
Do human subject safeguards matter to potential participants in psychiatric genetic research?
2019, Journal of Psychiatric ResearchCitation Excerpt :The recommendations included required independent assessments of participants’ decision-making capacity for studies presenting greater than minimal risk and procedures for involving alternative (surrogate) decision makers when participants were deemed to lack capacity. However, such calls for more stringent regulations for studies involving people with psychiatric disorders met with strong criticism from the psychiatric research community (Carpenter and Conley, 1999; Charney, 1999; Roberts and Roberts, 1999) and other important stakeholders, including family members and advocates of people with mental illness (Public comments, 1998). Such criticism was based upon ethically principled arguments (justice and fairness in the burdens and benefits of research; autonomy of individual participants), as well as empirical evidence on research-related decision-making abilities of individuals with mental disorders.
Psychotropic implant can be a new hope in psychiatry
2017, Asian Journal of PsychiatryCitation Excerpt :So it is better to treat and stabilize the patients with oral medication first. Once patient reaches remission or recovery phase of illness, a meaningful discussion about ‘risk without direct benefit' protocols should be made and psychotropic implant option can be given (Carpenter and Conley, 1999). Another issue with an implant is a potential risk of misuse, diversion and abuse.
Picturing neuroscience research through a human rights lens: Imaging first-episode schizophrenic treatment-naive individuals
2012, International Journal of Law and PsychiatryCitation Excerpt :We recommend that, given the often acute nature of potential participants' symptoms, all imaging studies involving FESTNIs be designed so to assess the capacity and consent of potential participants on an individual and task-specific basis. We hasten to add, however, that capacity assessments should be based on cognitive ability (Carpenter & Conley, 1999); a diagnosis of schizophrenia does not entail a lack of capacity. Our third set of recommendations concerns the delay of therapeutic procedures.
Why is recruitment to trials difficult? An investigation into recruitment difficulties in an RCT of supported employment in patients with severe mental illness
2009, Contemporary Clinical TrialsCitation Excerpt :Failure to recruit enough patients can result in early closure of the trial, unanswered scientific questions and wasted research resources. There may be particular difficulties in recruiting patients with severe mental illness into RCTs due to concerns about their potential vulnerability and reduced decision-making capacity [8]. However there is a lack of published research into whether patients with severe mental illness are difficult to recruit and why this may occur.
Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia
2002, NeuropsychopharmacologyAdverse events during a placebo phase for inpatients with chronic schizophrenia
2001, Biological PsychiatryCitation Excerpt :Suicidal ideation occurred rarely but was always controllable through the use of precaution measures, such as restriction to unit and increased observation. These findings support our prior analysis (Wyatt et al 1999) and other reviews (Carpenter and Conley 1999; Carpenter 1997; Carpenter et al 1997; Gilbert et al 1995) suggesting that the risks associated with placebo periods are reasonable and manageable for most inpatients with chronic schizophrenia. The second intriguing finding, and one that supports conclusions from our previous analysis, came from comparing the frequency and severity of events.